Avsola® and Inflectra® will be the preferred infliximab products for commercial members, starting April 1

Starting April 1, 2022, the following drugs will be designated as the preferred infliximab products for Blue Cross Blue Shield of Michigan and Blue Care Network group and individual commercial members:

The following products will be designated as nonpreferred infliximab products:

Note: Because the change in preferred drugs isn’t retroactive, existing authorizations aren't affected by this change. Prior authorization and site-of-care requirements continue to apply.

Some Blue Cross commercial groups not subject to these requirements

For Blue Cross commercial groups, this authorization requirement applies only to groups that currently participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit. To determine whether a group participates in the prior authorization program, see the Specialty Pharmacy Prior Authorization Master Opt-in/out Group list (PDF).

Note: To determine whether this change affects Blue Cross and Blue Shield Federal Employee Program® members and UAW Retiree Medical Benefits Trust (non-Medicare) members, refer to the group-specific drug lists, which you can find on the Blue Cross Medical Benefit Drugs page on our ereferrals.bcbsm.com website.

List of requirements

For a full list of requirements related to drugs covered under the medical benefit, see the Blue Cross and BCN utilization management medical drug list for Blue Cross commercial and BCN commercial members (PDF).

Note: This change will be reflected in the requirements list prior to April 1st.

Posted: January 2022
Lines of business: Blue Cross Blue Shield of Michigan and Blue Care Network